Medtronic's Penditure™ LAA Exclusion System: The Only Retrievable, Repositionable Left Atrial Appendage Clip Gains CE Mark and Surpasses 10,000 Global Implants

In Medtronic's latest earnings report for the first quarter of fiscal year 2026, Penditude was listed as the driver of low double-digit growth in the cardiac surgery business.

The Penditure Left Atrial Appendage Occlusion System is a clip specifically designed for cardiac surgery, used by surgeons to close the left atrial appendage (LAA). In 2023, Medtronic acquired Syntheon, adding Penditure to its product portfolio.

Medtronic emphasized that Penditure is currently on the marketThe Only OneLeft Atrial Appendage Clamps That Can Be Retrieved, Repositioned, and Redeployed by Surgeons During the Operation. This feature provides greater flexibility and precision for surgeons during the operation, which helps improve the success rate of the surgery and the treatment outcome for patients.

Since its launch, Penditure has performed well in the market. This week, Medtronic revealed,The global sales volume of its Penditure device has successfully broken through the 10,000-unit mark.

However, in the cardiac surgery device market, Penditure faces fierce competition, with its direct competitor being AtriCure's AtriClip. AtriClip received FDA approval in 2010 and obtained the CE mark in 2009. Since then, AtriCure has continuously upgraded the product and expanded its indications, receiving the CE mark for an upgraded version of the device in 2016 and for expanded indications in 2024.

In terms of market performance, AtriClip has also achieved remarkable results. In the first half of this year, international sales of AtriCure's appendage management products increased by 26%, reaching 20.5 million US dollars; during the same period, sales of these devices in the United States amounted to 87.2 million US dollars.

Unlike Abbott's Amplatzer Amulet and Boston Scientific's Watchman, AtriClip and Penditure mainly target patient groups undergoing heart surgery for other reasons, carving out a unique competitive space for them in specific markets.

As Penditure obtains the CE mark and is about to launch in the European market, the competition between Medtronic and AtriCure will undoubtedly become even more intense. This competition will not only drive continuous advancements in cardiac surgery device technology but also provide patients with more and better treatment options. In the future, Penditure's performance in the market deserves close attention from the healthcare industry and a wide range of patients.